Search

10X Genomics Inc (Class A)

Fermé

SecteurSoins de santé

46.37 -3.5

Résumé

Variation du prix de l'action

24h

Actuel

Min

46.01

Max

47.26

Chiffres clés

By Trading Economics

Revenu

2.8M

-13M

Ventes

-15M

151M

BPA

0.07

Marge bénéficiaire

-8.93

Employés

1,178

EBITDA

19M

-937K

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

-13.08% downside

Dividendes

By Acuity

Prochains Résultats

6 août 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

2.7B

5.5B

Ouverture précédente

49.87

Clôture précédente

46.37

Sentiment de l'Actualité

By Acuity

100%

0%

324 / 340 Classement par Healthcare

10X Genomics Inc (Class A) Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 juil. 2026, 16:26 UTC

10X Genomics Inc shares declined during Friday's session, hitting a session low before a slight recovery. The stock remains above its 20-day moving average.

23 juil. 2026, 23:26 UTC

Correlated Moves

10X Genomics Inc shares declined in after-market trading, mirroring a broader market trend. The stock remains near the upper end of its one-month range.

22 juil. 2026, 19:51 UTC

Correlated Moves

10X Genomics Inc reports a first-quarter net loss of -$34 million, with revenue falling to $47 million, as shares trade lower amid broader market declines.

21 juil. 2026, 19:53 UTC

Correlated Moves

Positive investor sentiment drives 10X Genomics Inc higher amid a broader market recovery, reflecting gains since Monday's close and aligning with small-cap stock interest.

20 juil. 2026, 19:16 UTC

News
Correlated Moves

10X Genomics Inc. shares are lower as a report cites only 1.1% annual sales growth and ineffective growth strategies amid a declining Life Sciences Tools sector.

Comparaison

Variation de prix

10X Genomics Inc (Class A) prévision

Objectif de Prix

By TipRanks

-13.08% baisse

Prévisions sur 12 Mois

Moyen 40.22 USD  -13.08%

Haut 50 USD

Bas 23 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

3

Achat

8

Maintien

0

Vente

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos 10X Genomics Inc (Class A)

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
help-icon Live chat